Lobbying organisation

Canadian Organization for Rare Disorders

8 meetings with public office holders, Oct 10, 2025 to Jul 30, 2026, on 1 bill Arena tracks.

23 meetings on record since 2017, their first on record.

Meetings over time

Oct 20251 meetingLuc Theriault
Oct 2025: 1 meeting, with Luc Theriault
Nov 20250 meetings
Nov 2025: 0 meetings
Dec 20250 meetings
Dec 2025: 0 meetings
Jan 20260 meetings
Jan 2026: 0 meetings
Feb 20260 meetings
Feb 2026: 0 meetings
Mar 20260 meetings
Mar 2026: 0 meetings
Apr 20260 meetings
Apr 2026: 0 meetings
May 20265 meetingsSandenga Yeba, Justine Frame, Marcus Powlowski, Daniel MacDonald, Helena Jaczek
May 2026: 5 meetings, with Sandenga Yeba, Justine Frame, Marcus Powlowski, Daniel MacDonald, Helena Jaczek
Jun 20261 meetingTom Kmiec
Jun 2026: 1 meeting, with Tom Kmiec
Jul 20261 meetingRaquel Dancho
Jul 2026: 1 meeting, with Raquel Dancho

Oct 2025peak 5 in a monthJul 2026

Hover or focus a month to see who was met.

What they lobby about

The registry's own subject categories, chosen by the lobbyist on each filing. Each one opens its own page.

Bills they lobbied on

C-265An Act to amend the Food and Drugs Act (List of Therapeutic Products Pre-approved for Special Access)5
Discussions on the implications of Bill C-265 An Act to amend the Food and Drugs Act (List of Therapeutic Products Pre-approved for Special Access) for patients’ access to drugs for rare diseases.
- Daniel MacDonald · Director General, Office of Pharmaceutical Management Strategies · Health Canada (HC)
- Justine Frame · Policy Advisor · Health Canada (HC)
- Sandenga Yeba · Director of Policy & Deputy Chief of Staff · Health Canada (HC)

Who they met

Conservative2 met · 2 meetings

Liberal2 met · 2 meetings

Bloc1 met · 1 meeting

Luc Theriault

Not in Arena's member list4 met · 4 meetings

Daniel MacDonald
Justine Frame
Mackenzy Metcalfe
Sandenga Yeba

House of Commons (5) · Health Canada (HC) (3) · Finance Canada (FIN) (1)

In their own words

Enhancement to Canada's regulatory and funding environment for new rare disease medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions to improve access for rare disease patients.
Establish Innovation, Science and Economic Development Canada policies related to research and development of treatments for rare disorders

Meetings from the Commissioner of Lobbying of Canada. Canada does not require lobbyists to disclose what they spend, so there is no lobbying budget to report here — only the meetings they filed.